What is the recommended dosage and treatment protocol for mirtazapine in treating major depressive disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mirtazapine Dosing and Treatment Protocol for Major Depressive Disorder

Start mirtazapine at 15 mg once daily at bedtime, and if inadequate response occurs, titrate up to a maximum of 45 mg daily, with dose changes made no more frequently than every 1-2 weeks. 1

Initial Dosing and Titration

  • Begin with 15 mg orally once daily, preferably in the evening prior to sleep 1
  • If patients do not achieve adequate response at 15 mg, increase the dose up to a maximum of 45 mg per day 1
  • Wait at least 1-2 weeks between dose adjustments to allow sufficient time to evaluate response to each dose level 1
  • The effective dose range is 15-45 mg once daily, with the long half-life (20-40 hours) supporting once-daily bedtime dosing 2

Timeline for Response Assessment

  • Begin assessing therapeutic response and adverse effects within 1-2 weeks of treatment initiation 3
  • Mirtazapine demonstrates a faster onset of action compared to SSRIs like fluoxetine, paroxetine, and sertraline, with some patients showing improvement in sleep disturbances and anxiety within the first week 4, 3, 2
  • Clinical antidepressant effect typically occurs within 2-4 weeks 2
  • If inadequate response occurs within 6-8 weeks, treatment modification is strongly recommended 3

Duration of Treatment

  • Continue treatment for 4-9 months after achieving satisfactory response in patients with a first episode of major depressive disorder 3
  • For patients with 2 or more prior depressive episodes, consider even longer duration of therapy to prevent relapse 3

Pre-Treatment Screening

  • Screen all patients for personal or family history of bipolar disorder, mania, or hypomania before initiating mirtazapine 1

Drug Interactions Requiring Dose Adjustment

  • With strong CYP3A inducers (carbamazepine, phenytoin, rifampin): Increase mirtazapine dose; decrease dose if inducer is discontinued 1
  • With strong CYP3A4 inhibitors (ketoconazole, clarithromycin): Decrease mirtazapine dose; increase dose if inhibitor is discontinued 1
  • With cimetidine: Decrease mirtazapine dose; increase dose if cimetidine is discontinued 1

MAOI Interactions

  • Allow at least 14 days between discontinuing an MAOI and starting mirtazapine 1
  • Allow at least 14 days after stopping mirtazapine before starting an MAOI 1

Common Side Effects to Monitor

  • Sedation/somnolence is the most common side effect due to H1 receptor antagonism 3, 5, 2
  • Increased appetite and weight gain occur frequently 3, 5, 2
  • Dry mouth 3
  • Dizziness 5
  • Transient elevations in cholesterol levels and liver function tests 5
  • Sleep disorders, constipation, or diarrhea 3

Clinical Advantages

  • Particularly suitable for patients with depression accompanied by insomnia or weight loss, as mirtazapine promotes sleep, appetite, and weight gain 3
  • Effective for patients with depression and anorexia 3
  • Minimal cardiovascular and anticholinergic effects 2
  • Essentially lacks serotonergic side effects such as gastrointestinal symptoms and sexual dysfunction 2

Treatment-Resistant Depression

  • Approximately 38% of patients do not achieve treatment response during 6-12 weeks of second-generation antidepressant treatment 4
  • If inadequate response to mirtazapine occurs, consider switching to an SSRI or SNRI, or adding another antidepressant with a different mechanism of action 3
  • Mirtazapine showed symptomatic improvement in 38% of treatment-resistant depression patients in open-label studies at a mean dose of 36.7 mg/day 6

Discontinuation

  • Gradually reduce the dosage rather than stopping abruptly whenever possible to minimize withdrawal symptoms 1

Safety in Overdose

  • Overdoses up to 975 mg caused significant sedation but no cardiovascular or respiratory effects or seizures 2

References

Guideline

Mirtazapine Treatment Guidelines for Major Depressive Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Other Antidepressants.

Handbook of experimental pharmacology, 2019

Research

Mirtazapine for treatment-resistant depression: a preliminary report.

Journal of psychiatry & neuroscience : JPN, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.